Indication
Nasopharyngeal Squamous Cell Carcinoma
3 clinical trials
2 products
4 drugs
Clinical trial
Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)Status: Terminated, Estimated PCD: 2023-11-15
Product
BirinapantClinical trial
Early-Phase Open-label Study of Tolinapant and Radiation in Cisplatin-Ineligible Patients With Previously Untreated, Locally Advanced Head and Neck CancerStatus: Recruiting, Estimated PCD: 2025-10-21
Product
TolinapantClinical trial
Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck.Status: Active (not recruiting), Estimated PCD: 2027-11-04
Drug
carboplatinDrug
AbraxaneDrug
fluorouracilDrug
hydroxyurea